{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:56:13Z","timestamp":1793318173504,"version":"4.5.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Exacerbations of chronic obstructive pulmonary disease (COPD) are heterogeneous with respect to inflammation and etiology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Investigate biomarker expression in COPD exacerbations to identify biologic clusters and determine biomarkers that recognize clinical COPD exacerbation phenotypes, namely those associated with bacteria, viruses, or eosinophilic airway inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with COPD were observed for 1 year at stable and exacerbation visits. Biomarkers were measured in sputum and serum. Viruses and selected bacteria were assessed in sputum by polymerase chain reaction and routine diagnostic bacterial culture. Biologic phenotypes were explored using unbiased cluster analysis and biomarkers that differentiated clinical exacerbation phenotypes were investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>A total of 145 patients (101 men and 44 women) entered the study. A total of 182 exacerbations were captured from 86 patients. Four distinct biologic exacerbation clusters were identified. These were bacterial-, viral-, or eosinophilic-predominant, and a fourth associated with limited changes in the inflammatory profile termed \u201cpauciinflammatory.\u201d Of all exacerbations, 55%, 29%, and 28% were associated with bacteria, virus, or a sputum eosinophilia. The biomarkers that best identified these clinical phenotypes were sputum IL-1\u03b2, 0.89 (area under receiver operating characteristic curve) (95% confidence interval [CI], 0.83\u20130.95); serum CXCL10, 0.83 (95% CI, 0.70\u20130.96); and percentage peripheral eosinophils, 0.85 (95% CI, 0.78\u20130.93), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The heterogeneity of the biologic response of COPD exacerbations can be defined. Sputum IL-1\u03b2, serum CXCL10, and peripheral eosinophils are biomarkers of bacteria-, virus-, or eosinophil-associated exacerbations of COPD. Whether phenotype-specific biomarkers can be applied to direct therapy warrants further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201104-0597oc","type":"journal-article","created":{"date-parts":[[2011,6,17]],"date-time":"2011-06-17T19:30:30Z","timestamp":1308339030000},"page":"662-671","source":"Crossref","is-referenced-by-count":909,"title":["Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Identification of Biologic Clusters and Their Biomarkers"],"prefix":"10.1093","volume":"184","author":[{"given":"Mona","family":"Bafadhel","sequence":"first","affiliation":[{"name":"Institute for Lung Health, and"},{"name":"Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"McKenna","sequence":"additional","affiliation":[{"name":"Institute for Lung Health, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Terry","sequence":"additional","affiliation":[{"name":"Institute for Lung Health, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Mistry","sequence":"additional","affiliation":[{"name":"Institute for Lung Health, and"},{"name":"Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlene","family":"Reid","sequence":"additional","affiliation":[{"name":"Institute for Lung Health, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranabashis","family":"Haldar","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"McCormick","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koirobi","family":"Haldar","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Kebadze","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Heart and Lung Institute, Centre for Respiratory Infections, Imperial College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelyse","family":"Duvoix","sequence":"additional","affiliation":[{"name":"Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Lindblad","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Chemistry, University of Uppsala, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemu","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rugman","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dodson","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Jenkins","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Saunders","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Newbold","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth H.","family":"Green","sequence":"additional","affiliation":[{"name":"Institute for Lung Health, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Venge","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Chemistry, University of Uppsala, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Lomas","sequence":"additional","affiliation":[{"name":"Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Barer","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom"},{"name":"Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian L.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Heart and Lung Institute, Centre for Respiratory Infections, Imperial College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[{"name":"Institute for Lung Health, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Brightling","sequence":"additional","affiliation":[{"name":"Institute for Lung Health, and"},{"name":"Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,9,15]]},"reference":[{"key":"2026032101234710500_bib1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"176","author":"Rabe","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234710500_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/thx.2004.021113","article-title":"NICE guidance for COPD","volume":"59","author":"Halpin","year":"2004","journal-title":"Thorax"},{"key":"2026032101234710500_bib3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/thorax.55.2.114","article-title":"Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations","volume":"55","author":"Bhowmik","year":"2000","journal-title":"Thorax"},{"key":"2026032101234710500_bib4","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1164\/ajrccm.150.6.7952628","article-title":"Airway eosinophilia in chronic bronchitis during exacerbations","volume":"150","author":"Saetta","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234710500_bib5","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1164\/rccm.200506-859OC","article-title":"Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations","volume":"173","author":"Papi","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234710500_bib6","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1164\/ajrccm.164.9.2105011","article-title":"Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease","volume":"164","author":"Seemungal","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234710500_bib7","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1056\/NEJMra0800353","article-title":"Infection in the pathogenesis and course of chronic obstructive pulmonary disease","volume":"359","author":"Sethi","year":"2008","journal-title":"N Engl J Med"},{"key":"2026032101234710500_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0091-6749(78)90137-9","article-title":"Response to corticosteroids in chronic bronchitis","volume":"62","author":"Shim","year":"1978","journal-title":"J Allergy Clin Immunol"},{"key":"2026032101234710500_bib9","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1164\/ajrccm.158.5.9804028","article-title":"Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis","volume":"158","author":"Pizzichini","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234710500_bib10","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0140-6736(00)02872-5","article-title":"Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial","volume":"356","author":"Brightling","year":"2000","journal-title":"Lancet"},{"key":"2026032101234710500_bib11","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/thorax.58.8.680","article-title":"Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis","volume":"58","author":"White","year":"2003","journal-title":"Thorax"},{"key":"2026032101234710500_bib12","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1378\/chest.117.6.1638","article-title":"Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD","volume":"117","author":"Stockley","year":"2000","journal-title":"Chest"},{"issue":"2","key":"2026032101234710500_bib13","first-page":"CD004403","article-title":"Antibiotics for exacerbations of chronic obstructive pulmonary disease","author":"Ram","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032101234710500_bib14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","article-title":"Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease","volume":"106","author":"Anthonisen","year":"1987","journal-title":"Ann Intern Med"},{"key":"2026032101234710500_bib15","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1086\/423959","article-title":"Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease","volume":"39","author":"van d","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2026032101234710500_bib16","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa023161","article-title":"Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease","volume":"348","author":"Aaron","year":"2003","journal-title":"N Engl J Med"},{"key":"2026032101234710500_bib17","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0140-6736(98)11326-0","article-title":"Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial","volume":"354","author":"Davies","year":"1999","journal-title":"Lancet"},{"key":"2026032101234710500_bib18","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJM199906243402502","article-title":"Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group","volume":"340","author":"Niewoehner","year":"1999","journal-title":"N Engl J Med"},{"key":"2026032101234710500_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1465-9921-8-30","article-title":"Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review","volume":"8","author":"Puhan","year":"2007","journal-title":"Respir Res"},{"key":"2026032101234710500_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1741-7015-6-28","article-title":"Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbations with antibiotics? A systematic review","volume":"6","author":"Puhan","year":"2008","journal-title":"BMC Med"},{"key":"2026032101234710500_bib21","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.2010.672","article-title":"Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease","volume":"303","author":"Rothberg","year":"2010","journal-title":"JAMA"},{"key":"2026032101234710500_bib22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1164\/rccm.200912-1843CC","article-title":"Chronic obstructive pulmonary disease phenotypes: the future of COPD","volume":"182","author":"Han","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234710500_bib23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/09031936.00035210","article-title":"Use of cluster analysis to define COPD phenotypes","volume":"36","author":"Weatherall","year":"2010","journal-title":"Eur Respir J"},{"key":"2026032101234710500_bib24","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1056\/NEJMe1008184","article-title":"Frequent exacerbations of chronic obstructive pulmonary disease: a distinct phenotype?","volume":"363","author":"Tashkin","year":"2010","journal-title":"N Engl J Med"},{"issue":"5, Suppl 2","key":"2026032101234710500_bib25","doi-asserted-by":"crossref","first-page":"398S","DOI":"10.1378\/chest.117.5_suppl_2.398S","article-title":"Toward a consensus definition for COPD exacerbations","volume":"117","author":"Rodriguez-Roisin","year":"2000","journal-title":"Chest"},{"key":"2026032101234710500_bib26","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/thx.53.11.953","article-title":"Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease","volume":"53","author":"Bhowmik","year":"1998","journal-title":"Thorax"},{"key":"2026032101234710500_bib27","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1053\/rmed.2001.1195","article-title":"Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability","volume":"95","author":"Brightling","year":"2001","journal-title":"Respir Med"},{"key":"2026032101234710500_bib28","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1183\/09031936.93.01060560","article-title":"Measuring health status in chronic airflow limitation","volume":"1","author":"Guyatt","year":"1988","journal-title":"Eur Respir J"},{"key":"2026032101234710500_bib29","first-page":"3","article-title":"Investigation of bronchoalveolar lavage, sputum and associated specimens","volume":"57","author":"Health Protection Agency 2009","year":"2009","journal-title":"National Standard Method BSOP"},{"key":"2026032101234710500_bib30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1136\/jcp.48.8.719","article-title":"Simple method for quantifying viable bacterial numbers in sputum","volume":"48","author":"Pye","year":"1995","journal-title":"J Clin Pathol"},{"key":"2026032101234710500_bib31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/thx.2004.027441","article-title":"Aetiological role of viral and bacterial infections in acute adult lower respiratory tract infection (LRTI) in primary care","volume":"61","author":"Creer","year":"2006","journal-title":"Thorax"},{"key":"2026032101234710500_bib32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200407-894OC","article-title":"Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma","volume":"171","author":"Bisgaard","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234710500_bib33","first-page":"24s","article-title":"Analysis of fluid-phase mediators","volume":"37","author":"Kelly","year":"2002","journal-title":"Eur Respir J Suppl"},{"key":"2026032101234710500_bib34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1164\/rccm.200604-506OC","article-title":"Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease","volume":"174","author":"Hurst","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234710500_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1164\/rccm.200705-678OC","article-title":"Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease","volume":"177","author":"Bozinovski","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234710500_bib36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1164\/rccm.200505-704OC","article-title":"Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease","volume":"173","author":"Hurst","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234710500_bib37","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1183\/09031936.00175109","article-title":"Clinical COPD phenotypes: a novel approach using principal component and cluster analyses","volume":"36","author":"Burgel","year":"2010","journal-title":"Eur Respir J"},{"key":"2026032101234710500_bib38","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N Engl J Med"},{"key":"2026032101234710500_bib39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00001648-200005000-00006","article-title":"Eosinophilia is associated with increased all-cause mortality after a follow-up of 30 years in a general population sample","volume":"11","author":"Hospers","year":"2000","journal-title":"Epidemiology"},{"key":"2026032101234710500_bib40","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1164\/ajrccm.160.6.9811041","article-title":"Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample","volume":"160","author":"Hospers","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234710500_bib41","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/archinte.165.8.891","article-title":"Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease","volume":"165","author":"Rosell","year":"2005","journal-title":"Arch Intern Med"},{"key":"2026032101234710500_bib42","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1183\/09031936.00036709","article-title":"Defective macrophage phagocytosis of bacteria in COPD","volume":"35","author":"Taylor","year":"2010","journal-title":"Eur Respir J"},{"key":"2026032101234710500_bib43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/thx.2009.122291","article-title":"Diagnostic importance of pulmonary interleukin-1beta and interleukin-8 in ventilator-associated pneumonia","volume":"65","author":"Conway","year":"2010","journal-title":"Thorax"},{"key":"2026032101234710500_bib44","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1378\/chest.09-1541","article-title":"Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD","volume":"137","author":"Quint","year":"2010","journal-title":"Chest"},{"key":"2026032101234710500_bib45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1378\/chest.129.2.223","article-title":"Coinfection in exacerbations of COPD: a new frontier","volume":"129","author":"Sethi","year":"2006","journal-title":"Chest"},{"key":"2026032101234710500_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1741-7015-6-29","article-title":"The problems of meta-analysis for antibiotic treatment of chronic obstructive pulmonary disease, a heterogeneous disease: a commentary on Puhan et al","volume":"6","author":"Sethi","year":"2008","journal-title":"BMC Med"},{"key":"2026032101234710500_bib47","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJMoa012561","article-title":"New strains of bacteria and exacerbations of chronic obstructive pulmonary disease","volume":"347","author":"Sethi","year":"2002","journal-title":"N Engl J Med"},{"key":"2026032101234710500_bib48","doi-asserted-by":"crossref","first-page":"e8578","DOI":"10.1371\/journal.pone.0008578","article-title":"Disordered microbial communities in asthmatic airways","volume":"5","author":"Hilty","year":"2010","journal-title":"PLoS ONE"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/184\/6\/662\/67293386\/ajrccm_184_6_662.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/184\/6\/662\/67293386\/ajrccm_184_6_662.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:23:55Z","timestamp":1774070635000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/184\/6\/662\/8508538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,9,15]]},"published-print":{"date-parts":[[2011,9,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201104-0597oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,9]]},"published":{"date-parts":[[2011,9]]}}}